A few days ago, the domestic intelligent service platform “Haixin Zhihui” in the field of tumor diagnosis and treatment announced the completion of the B1 round of financing, with a financing amount of several hundred million yuan. This financing was led by the well-known fund Qiming Venture Capital, followed by Hepei Investment, and Probe Capital served as the exclusive financial advisor.
The company’s official website shows that Zhejiang Haixin Zhihui Technology Co., Ltd. is an artificial intelligence company focusing on tumors, mainly in the field of intelligent tumor diagnosis and treatment. Through in-depth cooperation with authoritative experts in the field of clinical oncology in China, my country’s first intelligent diagnosis and treatment system for tumor diseases has been developed. , to provide patients with personalized and precise treatment recommendations, and assist patients in treatment planning and whole-course management. The system has broken the monopoly of international manufacturers in this field. After multiple phases of large-scale clinical research, it has been recognized by top clinical oncologists in China.
It is understood that the proceeds from this financing will further accelerate the team’s talent echelon construction, increase efforts to introduce more senior talents in the industry, and continuously improve the construction of the tumor intelligent service business line, thereby expanding commercialization and marketization path. Li Yingyun, founder of Haixin Zhihui, said: “Haixin will fully invest in building a full-course oncology clinical service team, deeply cultivating various oncology departments, and working with the Chinese Society of Clinical Oncology (CSCO), in addition to the high-speed iteration of its own products and service systems, it will also Carry out the research and development and registration of related products in the whole course of tumor management.”
According to the data of Wisdom Buds, as of the latest, Zhejiang Haixin Zhihui Technology Co., Ltd. has more than 40 patents, except for two patents in 2020 The application will be filed in 2021, and the rest of the patents will be filed in 2021. From the perspective of patent status, the company currently has 33 patents under trial, accounting for about 72%; from the perspective of patent type, about 74% of the company’s patents are invention patents. From the company’s patent innovation word cloud, it can be seen that the company’s current patent layout mainly focuses on related technical fields such as output connections, changing states, and graphical user interfaces.